Home > Treatment Options > Tumor Suppressors > Clinical Trials >

AZD2014 (Vistusertib)

Last Updated: 12/27/19

Status: Currently a NF2 Clinical Trial

Chemical Structure, Vistusertib
Trade Name Vistusertib
Other Names AZD2014, AZD-2014, AZD 2014
Pharmaceutical Companies AstraZeneca
NF2 Trial Availability USA 2017
Taken By Pill (oral)
Tumor Target Recurrent Meningioma
NF2 Trials

  • Recruiting Trial: NCT02831257 | Neurofibromatosis 2 (NF2) - Meningioma | Phase 2: July 2016
  • Not Open: NCT03071874 | Multiple Meningioma | Phase 2: April 15, 2017
Inhibitor mammalian Target of Rapamycin (mTOR); Autophagy; mTORC1/mTORC2
Molecular Formula C25H30N6O3

Early trial results in individuals with neurofibromatosis type 2 (NF2 / MERLIN), so far indicate the treatment may help shrink Meningioma by up to eighteen percent (18%).

Also in Trials for:

  • Conditions
  • Stomach Neoplasms
  • Advanced Cancer
  • Solid Tumor
  • Prostate Cancer
  • Advanced Metastatic Breast Cancer
  • Glioblastoma Multiforme
  • Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
  • Advanced Solid Malignancies
  • Metastatic Clear Cell Renal Carcinoma
  • Meningioma
  • Breast Cancer|Malignant Female
  • Reproductive System Neoplasm
  • Neurofibromatosis 2|Meningioma
  • Triple-Negative Breast Cancer|Squamous Cell Lung Cancer|Non-squamous Cell Lung Cancer With KRAS Mutations|Non-squamous Cell Lung Cancer With Wild-type KRAS


  1. Apra, Caroline, Matthieu Peyre, and Michel Kalamarides. "Current treatment options for meningioma." Expert review of neurotherapeutics 18.3 (2018): 241-249. DOI: https://doi.org/10.1080/14737175.2018.1429920 | Source: https://www.tandfonline.com/doi/abs/10.1080/14737175.2018.1429920
  2. Pike Kurt G., Malagu Karine, Hummersone Marc G., Menear Keith A., Duggan Heather M.E., Gomez Sylvie, Martin Niall M.B., Ruston Linette, Pass Sarah L., "Pass Martin. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014." Bioorganic & Medicinal Chemistry Letters, (2013)
    Source: https://www.sciencedirect.com/science/article/pii/S0960894X13000413?via%3Dihub | DOI: 10.1016/j.bmcl.2013.01.019
  3. Ma Xiao-Dong, Qiu Ni, Yang Bo, He Qiao-Jun, Hu Yong-Zhou. "Novel quinoline-derived mTOR inhibitors with remarkable enzymatic and cellular activities: design, synthesis and biological evaluation." Med. Chem. Commun., (2016)
    Source: http://pubs.rsc.org/en/Content/ArticleLanding/2016/MD/C5MD00401B#!divAbstract | DOI: 10.1039/C5MD00401B
  4. "AZD2014" National Center for Biotechnology Information. PubChem Compound Database; CID=25262792, https://pubchem.ncbi.nlm.nih.gov/compound/25262792
  5. Mawrin, Christian. "Looking for the needle in the haystack: Proteome-based identification of treatment targets in NF2-related nervous system tumors." EBioMedicine 16 (2017): 6-7.
    Source: http://www.sciencedirect.com/science/article/pii/S2352396417300488| DOI: 10.1016/j.ebiom.2017.01.044
What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021